Accessibility Menu
 

Rein Therapeutics

(NASDAQ) RNTX

Current Price$1.24
Market Cap$32.60M
Since IPO (2017)-99%
5 Year-96%
1 Year-36%
1 Month+12%

Rein Therapeutics Financials at a Glance

Market Cap

$32.60M

Revenue (TTM)

$0.00

Net Income (TTM)

$58.88M

EPS (TTM)

$-2.64

P/E Ratio

-0.47

Dividend

$0.00

Beta (Volatility)

1.00 (Average)

Price

$1.24

Volume

184,562

Open

$1.33

Previous Close

$1.24

Daily Range

$1.16 - $1.37

52-Week Range

$1.02 - $2.40

RNTX News

No articles available.

RNTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rein Therapeutics

Industry

Biotechnology

Employees

11

CEO

Brian J. Windsor, PhD

Headquarters

Austin, TX 78758, US

RNTX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-83%

Return on Capital

-50%

Return on Assets

-1%

Earnings Yield

-2.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$32.60M

Shares Outstanding

26.29M

Volume

184.56K

Short Interest

0.00%

Avg. Volume

134.08K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$65.11M

EBITDA

$28.05M

Operating Cash Flow

$22.29M

Capital Expenditure

$0.00

Free Cash Flow

$22.29M

Cash & ST Invst.

$12.87M

Total Debt

$0.00

Rein Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$32.60M

N/A

Market Cap/Employee

$2.96M

N/A

Employees

11

N/A

Net Income

$5.58M

+4.5%

EBITDA

$5.58M

+4.5%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Net Cash

$4.05M

-77.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.10%

N/A

Return on Invested Capital

-49.56%

N/A

Free Cash Flow

$3.55M

+7.1%

Operating Cash Flow

$3.55M

+7.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATNMActinium Pharmaceuticals, Inc.
$1.11+1.83%
CELUCelularity Inc.
$1.22-3.94%
BEATHeartBeam, Inc.
$1.15-8.00%
KZRKezar Life Sciences, Inc.
$6.43-3.96%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$172.70-0.03%
INTCIntel
$43.87-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%

Questions About RNTX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.